

Special Issue

Nanoparticle-Based Therapeutic Delivery Systems in Cancer Therapy

Message from the Guest Editor

Exciting research in the field of nanotechnology has shown the importance of designing an optimized drug delivery system for cancer therapy. There have been advances in terms of surface-engineering nanoparticles with targeting moieties to localize and selectively deliver various therapies in primary and metastatic cancers. This Special Issue invites articles, reviews, and perspectives showcasing the strategies of nanoparticle-based targeted therapeutic delivery, development of tumor-microenvironment modulating agents, multimodal drug delivery agents combined with imaging and tumor-penetrating agents, along with novel approaches for ameliorating toxic side effects, improving stability, and reducing protein corona formation. We are interested in a variety of nanoparticles, including liposomes, polymers, peptides, exosomes, and inorganic nanoparticle carriers for payloads like hydrophobic/hydrophilic drugs, nucleic acids, aptamers, antibodies, and likewise. Innovative studies focusing on improved uptake to tissue of interest, better pharmacodynamic/pharmacokinetic profiles, and higher therapeutic indices shown in animal models would be of greater value to this issue.

Guest Editor

Dr. Anusha Aditya
Columbia University Irving Medical Centre, New York, NY, USA

Deadline for manuscript submissions

31 December 2025



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/227457

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).